Capivasertib for B-Cell Non-Hodgkin Lymphoma
This trial is testing a new drug for people with a certain kind of cancer that has come back or does not respond to treatment.
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are patients currently being accepted for this trial?
"From what is listed on clinicaltrials.gov, this trial is still looking for participants and is thus actively recruiting patients. The listing was created on 11/3/2021 and last updated on 11/2/2022."
Have there been similar medical studies to this one in the past?
"Capivasertib has been under research for just over a decade now. AstraZeneca first sponsored a trial in 2010, which resulted in Phase 1 approval after studying 285 patients. 23 different studies are ongoing as of now, conducted across 959 cities and 44 countries worldwide."
What is the target number of enrollees for this clinical trial?
"Yes, that is accurate. According to the information on clinicaltrials.gov, this particular trial was originally posted on 11/3/2021 and is currently looking for 272 patients from 6 different sites."
What was the outcome of Capivasertib's FDA hearing?
"Capivasertib's safety is only supported by phase 2 data, meaning that there is not yet any clinical evidence indicating that the drug is effective. However, it did receive a score of 2 because there are no major safety concerns at this time."
How many different hospitals are running this trial?
"Currently, there are six sites administering this trial with more locations in Victoria, Duarte and Los Angeles. To limit participant's travel burden, it is best to select a location closest to you."
Are middle-aged adults welcome in this research project?
"This particular clinical study is open to patients aged 18-130. In contrast, there are 320 trials for minors and 1666 studies available for elderly patients."
What else is known about Capivasertib from other research?
"As of now, 23 different clinical trials are underway to research Capivasertib. 4 of these trials have progressed to Phase 3. The majority of the tests for Capivasertib are being conducted in Montpellier, Ontario; however, 4213 unique locations around the world are running studies concerning Capivasertib."